Cargando…
The utility of molecular diagnostics to predict recurrence of head and neck carcinoma
BACKGROUND: Locoregional recurrence is the major cause of treatment failure after surgery for oral squamous cell carcinoma. Molecular diagnostics have the potential to improve on clinicopathological parameters to predict this recurrence and plan adjuvant treatment. The test most frequently applied i...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461148/ https://www.ncbi.nlm.nih.gov/pubmed/22918395 http://dx.doi.org/10.1038/bjc.2012.213 |
_version_ | 1782245043243843584 |
---|---|
author | Pena Murillo, C Huang, X Hills, A McGurk, M Lyons, A Jeannon, J-P Odell, E Brown, A Lavery, K Barrett, W Sherriff, M Brakenhoff, R Partridge, M |
author_facet | Pena Murillo, C Huang, X Hills, A McGurk, M Lyons, A Jeannon, J-P Odell, E Brown, A Lavery, K Barrett, W Sherriff, M Brakenhoff, R Partridge, M |
author_sort | Pena Murillo, C |
collection | PubMed |
description | BACKGROUND: Locoregional recurrence is the major cause of treatment failure after surgery for oral squamous cell carcinoma. Molecular diagnostics have the potential to improve on clinicopathological parameters to predict this recurrence and plan adjuvant treatment. The test most frequently applied is based on detecting TP53 mutations, but alternative methodology is required for cases that harbour the wild-type gene. METHODS: One hundred and two cases with tumour-adjacent margins, considered to be clear margins by microscopy, were examined using carefully optimised molecular diagnostics based on detection of the TP53 and Ly-6D markers. The markers were also combined to provide a dual approach. RESULTS: The dual molecular diagnostic identified cases with a significant increase in the probablility of developing locoregional recurrence when tumour-adjacent positive and clear margins were compared (P=0.0001). These tests were most useful when the clearance at the resection margins was 5 mm or less. The TP53-based diagnostic was a better predictor of locoregional recurrence than established clinicopathological parameters. CONCLUSION: The optimised TP53-based diagnostic rapidly identifies an important subgroup of cases with close margins that will benefit from new treatment modalities to reduce the risk of recurrence. |
format | Online Article Text |
id | pubmed-3461148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-34611482013-09-25 The utility of molecular diagnostics to predict recurrence of head and neck carcinoma Pena Murillo, C Huang, X Hills, A McGurk, M Lyons, A Jeannon, J-P Odell, E Brown, A Lavery, K Barrett, W Sherriff, M Brakenhoff, R Partridge, M Br J Cancer Molecular Diagnostics BACKGROUND: Locoregional recurrence is the major cause of treatment failure after surgery for oral squamous cell carcinoma. Molecular diagnostics have the potential to improve on clinicopathological parameters to predict this recurrence and plan adjuvant treatment. The test most frequently applied is based on detecting TP53 mutations, but alternative methodology is required for cases that harbour the wild-type gene. METHODS: One hundred and two cases with tumour-adjacent margins, considered to be clear margins by microscopy, were examined using carefully optimised molecular diagnostics based on detection of the TP53 and Ly-6D markers. The markers were also combined to provide a dual approach. RESULTS: The dual molecular diagnostic identified cases with a significant increase in the probablility of developing locoregional recurrence when tumour-adjacent positive and clear margins were compared (P=0.0001). These tests were most useful when the clearance at the resection margins was 5 mm or less. The TP53-based diagnostic was a better predictor of locoregional recurrence than established clinicopathological parameters. CONCLUSION: The optimised TP53-based diagnostic rapidly identifies an important subgroup of cases with close margins that will benefit from new treatment modalities to reduce the risk of recurrence. Nature Publishing Group 2012-09-25 2012-08-23 /pmc/articles/PMC3461148/ /pubmed/22918395 http://dx.doi.org/10.1038/bjc.2012.213 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Molecular Diagnostics Pena Murillo, C Huang, X Hills, A McGurk, M Lyons, A Jeannon, J-P Odell, E Brown, A Lavery, K Barrett, W Sherriff, M Brakenhoff, R Partridge, M The utility of molecular diagnostics to predict recurrence of head and neck carcinoma |
title | The utility of molecular diagnostics to predict recurrence of head and neck carcinoma |
title_full | The utility of molecular diagnostics to predict recurrence of head and neck carcinoma |
title_fullStr | The utility of molecular diagnostics to predict recurrence of head and neck carcinoma |
title_full_unstemmed | The utility of molecular diagnostics to predict recurrence of head and neck carcinoma |
title_short | The utility of molecular diagnostics to predict recurrence of head and neck carcinoma |
title_sort | utility of molecular diagnostics to predict recurrence of head and neck carcinoma |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461148/ https://www.ncbi.nlm.nih.gov/pubmed/22918395 http://dx.doi.org/10.1038/bjc.2012.213 |
work_keys_str_mv | AT penamurilloc theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT huangx theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT hillsa theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT mcgurkm theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT lyonsa theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT jeannonjp theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT odelle theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT browna theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT laveryk theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT barrettw theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT sherriffm theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT brakenhoffr theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT partridgem theutilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT penamurilloc utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT huangx utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT hillsa utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT mcgurkm utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT lyonsa utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT jeannonjp utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT odelle utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT browna utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT laveryk utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT barrettw utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT sherriffm utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT brakenhoffr utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma AT partridgem utilityofmoleculardiagnosticstopredictrecurrenceofheadandneckcarcinoma |